SLU-PP-332 Research Overview (also known as ERR agonist, SLU PP 332, Pan-ERR agonist)
A potent agonist of estrogen-related receptors ERRα and ERRγ — orphan nuclear receptors that regulate mitochondrial biogenesis and oxidative metabolism. SLU-PP-332 is studied as an exercise mimetic that dramatically increases endurance, fat oxidation, and mitochondrial density in skeletal muscle without physical exertion, and shows protective effects in heart failure models.
What Is SLU-PP-332?
SLU-PP-332 is a synthetic small-molecule pan-agonist of the estrogen-related receptor (ERR) subfamily — specifically ERRα, ERRβ, and ERRγ. These orphan nuclear receptors serve as master regulators of mitochondrial biogenesis and oxidative phosphorylation, and are the transcription factors that ultimately drive the aerobic capacity adaptations associated with endurance training.
Why ERR Receptors Are an Exercise Target
Exercise induces mitochondrial biogenesis and metabolic reprogramming through a cascade that eventually activates PGC-1α, which co-activates ERR receptors to transcribe hundreds of genes encoding mitochondrial proteins, fatty acid oxidation enzymes, and oxidative phosphorylation components. By directly activating ERR receptors, SLU-PP-332 bypasses the upstream exercise-induced signals and directly engages the downstream transcriptional machinery.
Preclinical Research Data
In mouse studies, SLU-PP-332 treatment for 4 weeks produced more than 70% improvement in treadmill running endurance, increased mitochondrial density in skeletal muscle, upregulated fatty acid oxidation gene expression, and reduced body fat. A separate research line showed that SLU-PP-332 significantly improved cardiac function and survival in a mouse model of heart failure — a finding with potential implications for cardiac rehabilitation.
Comparison with AICAR and Cardarine
SLU-PP-332 works through a distinct mechanism from both AICAR (AMPK activation) and Cardarine (PPARδ activation). Researchers exploring the full exercise-mimetic pathway are studying combinations targeting all three systems for potentially additive effects.
Research Indications
Metabolic Health
Weight Loss & Metabolic Syndrome
Preclinical studies show 12% body weight reduction in 28 days with 25% increased fat oxidation. Improved glucose tolerance, insulin sensitivity, and reduced hepatic steatosis without appetite suppression.
Exercise Mimetic Effects
70% increase in endurance and 45% increase in running distance. Increased oxidative muscle fibers and mitochondrial density without physical exercise. Progressive grip strength improvements.
Anti-Aging & Longevity
First compound to reverse age-related mitochondrial dysfunction. Reduced cellular senescence markers and restored mitochondrial function in elderly animal models (21-month-old mice).
Cardiovascular
Cardiac Protection
Improved ejection fraction in heart failure models with reduced cardiac fibrosis and enhanced mitochondrial function. Decreased cardiac stress markers.
Kidney Health
Age-Related Kidney Disease
Reversed age-related kidney decline with reduced albuminuria, prevented podocyte loss, and restored kidney mitochondrial architecture in aging studies.
Research Protocols
As reported in cited literature and research-community logs (see Research Citations below) — not a personal dosing recommendation.
| Research Application | Dose | Frequency | Route |
|---|
| ⚠ RESEARCH USE ONLY — Standard metabolic protocol | 50 mg/kg (animal dosing) | Twice daily | IP injection |
| ⚠ RESEARCH USE ONLY — Acute exercise enhancement | 50 mg/kg (animal dosing) | Single dose 1 hour pre-exercise | IP injection |
| ⚠ RESEARCH USE ONLY — Extended protocol | 50 mg/kg (animal dosing) | Twice daily for 3–5 weeks | IP injection |
| HUMAN DOSING NOT ESTABLISHED | No approved human dosing | Awaiting clinical trials | Oral formulation in development |
Important Note
SLU-PP-332 has no established clinical trials in humans. All known doses derive from animal studies using IP administration (50–100 mg/kg in mice). Measurements and safe human doses cannot be determined until the compound advances to Phase I clinical trials. An oral formulation is reportedly in development.
Peptide Interactions
Both activate AMPK pathways; additive glucose-lowering may increase hypoglycemia risk. Monitoring blood glucose is essential if combining in research protocols.
SLU-PP-332 improves insulin sensitivity in preclinical models; combining with exogenous insulin may cause excessive blood glucose reduction.
Dual GLP-1/GIP agonism combined with ERR activation creates strong additive metabolic effects — compounding glucose lowering and weight-loss signals increases unpredictability.
GLP-1 pathway activation combined with ERR agonism produces additive metabolic effects. Risk of hypoglycemia is elevated; no combined safety data exists in any model.
Both target mitochondrial bioenergetics through complementary mechanisms (NNMT inhibition vs ERR activation). Preclinical evidence suggests no adverse interactions; potentially additive for energy expenditure.
NAD+ precursors feed directly into the mitochondrial energy pathways that SLU-PP-332 transcriptionally upregulates via ERRα/γ. Combination may amplify mitochondrial biogenesis and ATP production.
Growth hormone secretagogues operate through entirely distinct receptor pathways (GHRH-R). No known mechanistic conflict with ERR agonism; different tissue targets.
Natural ERRα modulator with mild AMPK-activating properties. May complement SLU-PP-332 through overlapping but distinct transcriptional targets; no adverse interactions identified in available literature.
Reported Research Timeline
01Early days (metabolic priming) (reported in cited studies): SLU-PP-332 activates estrogen-related receptors (ERRα/β/γ) and upregulates PGC-1α, triggering a metabolic state similar to sustained aerobic training. Subjective energy and endurance shifts have been noted in animal research contexts; the mechanistic changes precede performance outcomes.
02Weeks 2–4 (mitochondrial remodeling) (reported in cited studies): Murine data show increased mitochondrial biogenesis markers, upregulation of oxidative phosphorylation gene networks, and a shift toward fat oxidation as the primary fuel source. Cardiomyocyte hypertrophy and improved cardiac output have been documented in rodent models at this stage.
03Weeks 4–8 (endurance and composition effects) (reported in cited studies): Animal models showed 70% longer treadmill run-time after a 4-week protocol. Lean mass preservation and fat mass reduction occurred in parallel. Metabolic rate at rest increased as a consequence of improved mitochondrial density.
04Long-term research context (reported in cited studies): SLU-PP-332 remains an early-stage research compound. All documented outcomes are preclinical. Human translation of these findings is unconfirmed. Effects on lifespan and age-related metabolic decline are under active investigation as part of the exercise-mimetic research area.
Safety Notes
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
Oral Route Caveat: SLU-PP-332 was developed and validated exclusively via injectable (IP/SubQ) routes in all preclinical efficacy studies (Dharia et al., 2020; 2022). Oral bioavailability has not been characterized in published research. Researchers seeking to replicate published outcomes should use the injectable route.
FOR RESEARCH USE ONLY — animal studies show a favorable safety profile with no severe side effects at therapeutic doses used in published literature.
Well-tolerated in rodents with no observed liver, kidney, or cardiac toxicity at research doses. No observations of pancreatitis, abnormal bleeding, bone loss, or body temperature dysregulation.
Does not suppress endogenous hormones or act as a stimulant in preclinical models.
Minor changes in plasma cholesterol and triglycerides noted in some rodent studies — clinical significance in humans is unknown.
Potential interactions with insulin sensitivity — high additive interaction risk with diabetes medications (see Peptide Interactions).
Human safety profile is COMPLETELY UNKNOWN — extrapolation from animal studies to humans is unreliable for this compound class.
NEVER use experimental research compounds without medical supervision and appropriate regulatory framework.
Not for human consumption. SLU-PP-332 has no IND application, no Phase I safety data, and no approved human dose.
Stop Use and Seek Medical Attention If:
If you have obtained SLU-PP-332 outside approved research protocols, STOP IMMEDIATELY
Any cardiovascular symptoms — chest pain, palpitations, shortness of breath
Severe hypoglycemia — especially if combining with diabetes medications
Signs of liver dysfunction: jaundice, dark urine, severe abdominal pain
Signs of kidney problems: reduced urination, swelling, severe back pain
Unusual fatigue, dizziness, or unexplained metabolic disturbances
Severe headaches or neurological symptoms
Allergic reactions: rash, hives, difficulty breathing, swelling
Any unexpected or concerning symptoms — seek immediate medical attention
Consult qualified medical professionals before considering any experimental compound
Quality Indicators
Verified Marker
Insoluble in Water — Use DMSO
SLU-PP-332 is a lipophilic small molecule that will not dissolve in water-based solvents. Use DMSO as the primary solvent (stock up to 50–100 mg/mL). If a supplier claims water solubility, the product is mislabeled or adulterated.
Acceptable Range
Research Chemical Only — Not for Human Use
SLU-PP-332 is not FDA-approved and has no IND application. It is legally available only for legitimate in vitro and in vivo research purposes through licensed chemical suppliers.
Quality Concern
Products Marketed for Human Consumption
Any SLU-PP-332 marketed or sold as intended for human consumption is illegal and potentially dangerous. All legitimate product listings must carry clear "For Research Use Only" labeling with proper regulatory declarations.
Quality Concern
Unknown Purity or No Certificate of Analysis
SLU-PP-332 requires independent purity verification (HPLC or MS-confirmed ≥98%). Without a verified CoA, purity and identity cannot be confirmed. Contaminated or mislabeled compounds pose serious health risks.
Quality Concern
No GMP Standards Exist for This Compound
Since SLU-PP-332 is not approved for human use, there are no GMP or USP monograph standards. Quality varies widely between suppliers — source only from reputable chemical suppliers with published analytical data.
Verified Marker
Legitimate Research Supplier
A reliable supplier provides a Certificate of Analysis (CoA) showing batch number, molecular structure confirmation, HPLC purity (≥98%), and mass spectrometry data. Sources: Cayman Chemical, MedChemExpress, Sigma-Aldrich research division, or equivalent.
Research Citations
"
Research Focus
Exercise mimicry, Endurance enhancement, Mitochondrial biogenesis, Heart failure, Fat oxidation, Metabolic health
Verified Vendors Carrying SLU-PP-332
Frequently Asked Questions
What should researchers watch for with SLU-PP-332?
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
What should researchers expect over time with SLU-PP-332?
Early days (metabolic priming) (reported in cited studies): SLU-PP-332 activates estrogen-related receptors (ERRα/β/γ) and upregulates PGC-1α, triggering a metabolic state similar to sustained aerobic training. Subjective energy and endurance shifts have been noted in animal research contexts; the mechanistic changes precede performance outcomes.
How is SLU-PP-332 typically administered in research?
As reported in cited literature and research-community logs (see Research Citations below) — not a personal dosing recommendation.
Browse all peptides in the Encyclopedia →